Annual Revenue
$462.18 M
+$213.04 M+85.51%
31 December 2023
Summary:
Intra-Cellular Therapies annual revenue is currently $462.18 million, with the most recent change of +$213.04 million (+85.51%) on 31 December 2023. During the last 3 years, it has risen by +$439.64 million (+1951.28%). ITCI annual revenue is now at all-time high.ITCI Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Revenue
$175.16 M
+$13.88 M+8.61%
30 September 2024
Summary:
Intra-Cellular Therapies quarterly revenue is currently $175.16 million, with the most recent change of +$13.88 million (+8.61%) on 30 September 2024. Over the past year, it has increased by +$49.35 million (+39.23%). ITCI quarterly revenue is now at all-time high.ITCI Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Revenue
$612.78 M
+$49.35 M+8.76%
30 September 2024
Summary:
Intra-Cellular Therapies TTM revenue is currently $612.78 million, with the most recent change of +$49.35 million (+8.76%) on 30 September 2024. Over the past year, it has increased by +$194.68 million (+46.56%). ITCI TTM revenue is now at all-time high.ITCI TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ITCI Revenue Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +85.5% | +39.2% | +46.6% |
| 3 y3 years | +1951.3% | +710.7% | +793.3% |
| 5 y5 years | - | - | - |
ITCI Revenue High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +1951.3% | at high | +710.7% | at high | +793.3% |
| 5 y | 5 years | at high | +1951.3% | at high | >+9999.0% | at high | >+9999.0% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% | at high | >+9999.0% |
Intra-Cellular Therapies Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $175.16 M(+8.6%) | $612.78 M(+8.8%) |
| June 2024 | - | $161.28 M(+11.3%) | $563.43 M(+10.0%) |
| Mar 2024 | - | $144.84 M(+10.1%) | $512.29 M(+10.8%) |
| Dec 2023 | $462.18 M(+85.5%) | $131.51 M(+4.5%) | $462.18 M(+10.5%) |
| Sept 2023 | - | $125.81 M(+14.2%) | $418.10 M(+14.8%) |
| June 2023 | - | $110.13 M(+16.3%) | $364.16 M(+17.8%) |
| Mar 2023 | - | $94.73 M(+8.3%) | $309.11 M(+24.1%) |
| Dec 2022 | $249.13 M(+204.9%) | $87.43 M(+21.7%) | $249.13 M(+33.1%) |
| Sept 2022 | - | $71.87 M(+30.5%) | $187.22 M(+36.7%) |
| June 2022 | - | $55.07 M(+58.5%) | $136.95 M(+35.8%) |
| Mar 2022 | - | $34.76 M(+36.2%) | $100.88 M(+23.5%) |
| Dec 2021 | $81.71 M(+262.6%) | $25.52 M(+18.1%) | $81.71 M(+19.1%) |
| Sept 2021 | - | $21.61 M(+13.7%) | $68.60 M(+26.2%) |
| June 2021 | - | $19.01 M(+22.0%) | $54.36 M(+46.0%) |
| Mar 2021 | - | $15.58 M(+25.6%) | $37.23 M(+65.2%) |
| Dec 2020 | $22.53 M | $12.40 M(+68.3%) | $22.53 M(+122.5%) |
| Sept 2020 | - | $7.37 M(+292.8%) | $10.13 M(+267.1%) |
| June 2020 | - | $1.88 M(+112.6%) | $2.76 M(+212.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | $882.50 K(>+9900.0%) | $882.50 K(+258.9%) |
| Dec 2017 | $245.80 K(-25.7%) | $5100.00(-83.4%) | $245.90 K(-27.4%) |
| Sept 2017 | - | $30.80 K(-73.1%) | $338.70 K(+8.5%) |
| June 2017 | - | $114.70 K(+20.4%) | $312.30 K(-26.7%) |
| Mar 2017 | - | $95.30 K(-2.7%) | $426.00 K(+28.8%) |
| Dec 2016 | $330.70 K(+977.2%) | $97.90 K(+2125.0%) | $330.70 K(+63.1%) |
| Sept 2016 | - | $4400.00(-98.1%) | $202.80 K(+2.2%) |
| June 2016 | - | $228.40 K(-861.3%) | $198.40 K(+546.3%) |
| Dec 2015 | $30.70 K(-94.4%) | -$30.00 K(-152.3%) | $30.70 K(-86.1%) |
| June 2015 | - | $57.40 K(+1639.4%) | $221.20 K(-42.2%) |
| Mar 2015 | - | $3300.00(-90.9%) | $383.00 K(-30.0%) |
| Dec 2014 | $547.50 K(-80.0%) | $36.10 K(-71.0%) | $547.50 K(-59.1%) |
| Sept 2014 | - | $124.40 K(-43.2%) | $1.34 M(-28.9%) |
| June 2014 | - | $219.20 K(+30.6%) | $1.88 M(+13.2%) |
| Mar 2014 | - | $167.80 K(-79.7%) | $1.66 M(+11.2%) |
| Dec 2013 | $2.74 M(-12.2%) | $827.50 K(+23.9%) | $1.50 M(+123.9%) |
| Sept 2013 | - | $668.00 K | $668.00 K |
| Dec 2012 | $3.12 M | - | - |
FAQ
- What is Intra-Cellular Therapies annual revenue?
- What is the all time high annual revenue for Intra-Cellular Therapies?
- What is Intra-Cellular Therapies annual revenue year-on-year change?
- What is Intra-Cellular Therapies quarterly revenue?
- What is the all time high quarterly revenue for Intra-Cellular Therapies?
- What is Intra-Cellular Therapies quarterly revenue year-on-year change?
- What is Intra-Cellular Therapies TTM revenue?
- What is the all time high TTM revenue for Intra-Cellular Therapies?
- What is Intra-Cellular Therapies TTM revenue year-on-year change?
What is Intra-Cellular Therapies annual revenue?
The current annual revenue of ITCI is $462.18 M
What is the all time high annual revenue for Intra-Cellular Therapies?
Intra-Cellular Therapies all-time high annual revenue is $462.18 M
What is Intra-Cellular Therapies annual revenue year-on-year change?
Over the past year, ITCI annual revenue has changed by +$213.04 M (+85.51%)
What is Intra-Cellular Therapies quarterly revenue?
The current quarterly revenue of ITCI is $175.16 M
What is the all time high quarterly revenue for Intra-Cellular Therapies?
Intra-Cellular Therapies all-time high quarterly revenue is $175.16 M
What is Intra-Cellular Therapies quarterly revenue year-on-year change?
Over the past year, ITCI quarterly revenue has changed by +$49.35 M (+39.23%)
What is Intra-Cellular Therapies TTM revenue?
The current TTM revenue of ITCI is $612.78 M
What is the all time high TTM revenue for Intra-Cellular Therapies?
Intra-Cellular Therapies all-time high TTM revenue is $612.78 M
What is Intra-Cellular Therapies TTM revenue year-on-year change?
Over the past year, ITCI TTM revenue has changed by +$194.68 M (+46.56%)